CompletedPHASE1, PHASE2NCT01454596

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Intervention
Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL(biological)
Enrollment
18 enrolled
Eligibility
18-70 years · All sexes
Timeline
2012 – 2019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01454596 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma →

← Back to all trials